



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61F 2/02	A1	(11) International Publication Number: WO 91/03990 (43) International Publication Date: 4 April 1991 (04.04.91)
(21) International Application Number: PCT/US90/05028 (22) International Filing Date: 5 September 1990 (05.09.90) (30) Priority data: 408,059 15 September 1989 (15.09.89) US (71) Applicant: CHIRON OPHTHALMICS, INC. [US/US]; 9243 Jeronimo, Irvine, CA 92178 (US). (72) Inventors: REICH, Cary ; 26501 Dapple Grey Lane, Laguna Hills, CA 92653 (US). FORSBERG, Jeffrey ; 26 Remington, Irvine, CA 92720 (US). LEVY, Harold ; 4127 Birchwood, Seal Beach, CA 90740 (US). TONER-WEBB, Jean ; 1 Cresthaven, Irvine, CA 92714 (US).		(74) Agents: FIGG, E., Anthony et al.; Bernard, Rothwell & Brown, 1700 K Street, N.W. Suite 800, Washington, DC 20006 (US). (81) Designated States: AT (European patent), AU, BE (European patent), BR, CA, CH (European patent), DE (European patent)*, DK (European patent), ES (European patent), FR (European patent), GB (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), SE (European patent), SU. Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: METHOD FOR ACHIEVING EPITHELIALIZATION OF SYNTHETIC LENSES (57) Abstract <p>Synthetic surfaces such as surfaces of implantable prosthetic devices are modified to enhance their ability to support the growth, migration and attachment of epithelial cells. A surface modifier composition is covalently bound to the synthetic surface, and an epithelial cell-supporting coating is applied to the modified surface. The surface modifier composition may also include an epithelial cell-supporting material. The invention is particularly suited towards the modification of synthetic epikeratophakia lenses.</p>		

DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LJ	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
DE	Germany, Federal Republic of	LU	Luxembourg	TG	Togo
DK	Denmark			US	United States of America

METHOD FOR ACHIEVING EPITHELIALIZATION OF SYNTHETIC LENSES

Background of the Invention

1. Technical Field

5 The present invention relates to methods for
modifying synthetic surfaces to support the attachment,
growth and migration of epithelial cells both in vitro
and in vivo, as well as the modified surfaces
10 themselves. More specifically, the invention relates
to methods for modifying the tissue-contacting surfaces
of synthetic, implantable prosthetic devices,
especially contact lenses, to better support the
attachment, growth and migration of epithelial cells.
The invention also relates to the prosthetic devices
15 themselves.

2. Brief Description of the Background Art

 There are a number of prosthetic devices which
necessarily or desirably can be implanted either
completely or partially beneath epithelial tissues. It
20 is to be understood that reference to "epithelial"
tissues herein includes epidermal tissue as well as
other epithelial tissues. Implantation beneath the
epithelium may be done for purposes of fixation of the
device relative to other tissues and/or for cosmetic
25 purposes. Examples of implanted prostheses include
dental prostheses such as artificial teeth and
bridgework, hearing aids, dermal implants, vascular
access devices, such as those associated with hyper-

alimentation, colostomy devices and prosthetic corneas. While the present invention will be described with reference to prosthetic corneas for subepithelial implantation, and with specific reference to an epikeratophakia lens, it will be readily understood that the invention is not so limited.

The permanent implantation in the eye of a synthetic epikeratophakia lens has major advantages over operations such as radial keratotomy to correct severe vision problems. Implanting the synthetic epikeratophakia lens does not involve compromising the anterior chamber, for example. In the implantation procedure, the epithelial layer is removed via a trephine and scrape, the wound is undermined and the lens is tucked into place. Re-epithelialization of the lens is expected to result in a permanent correction of vision for the patient. By "re-epithelialization" it is meant not only the growth and migration (or 'spreading') of epithelial cells, but also the attachment and stabilization of these cells.

Re-epithelialization of the implant is important for a variety of reasons. For example, re-epithelialization is very important in order to ensure long term anchorage of an implant. The layer of new cells also acts as a barrier to prevent tear-born and other materials from depositing on the lens surface. Unfortunately, many materials which exhibit beneficial properties when formed into prosthetic devices (such as stability and lack of immune response) do not adequately support the growth, migration and attachment of epithelial cells.

The methods and modified synthetic surfaces of the present invention also are useful for the in vitro growth of epithelial cells. Epithelial cells grown in

the laboratory upon surfaces modified according to the present invention exhibit attachment, growth and migration quite similar to the in vivo growth pattern of epithelial cells.

5 Summary of the Invention

In one aspect, the present invention relates to a method for modifying a synthetic surface, comprising applying to a synthetic surface a surface modifying composition comprising a polymer having pendant
10 functional groups capable of being converted to nitrene groups and then converting the functional groups to nitrenes and thereby covalently binding the surface modifying composition to the synthetic surface. The surface modifying composition optionally includes a
15 material which supports or enhances the attachment, growth and migration of epithelial cells.

In another aspect, the present invention relates to a method for coating a synthetic surface with an epithelial cell-supporting coating, comprising applying
20 to a synthetic surface a surface modifying composition comprising a polymer having pendant functional groups capable of being converted to nitrene groups, converting the functional groups to nitrene groups and thereby covalently binding the surface modifying
25 composition to the polymeric surface to thereby modify the synthetic surface, and subsequently applying an epithelial cell-supporting coating onto the modified synthetic surface. In a preferred embodiment, the epithelial cell supporting coating is provided as a
30 plurality of layers to more closely resemble native tissues. The coating also may be crosslinked so that it is stabilized and resistant to the action of proteases.

The present invention also relates to the modified synthetic surfaces per se. Thus, one aspect of the invention relates to a modified synthetic surface for supporting the attachment, growth and migration of epithelial cells, comprising a synthetic surface and a surface modifying composition covalently bound to the synthetic surface, wherein the surface modifying composition is capable of supporting epithelial cells.

In another aspect the invention provides a modified synthetic surface for supporting the growth and migration of epithelial cells, comprising a synthetic surface, a surface modifying composition covalently bound to the synthetic surface, and an epithelial cell supporting coating disposed on the modified surface.

The invention also provides a treated prosthetic device for subepithelial implantation in a human or animal comprising a prosthetic device having a surface modifying composition covalently bound thereto, the surface modifying composition comprising a polymer having a plurality of pendant amino or carboxyl groups, and an epithelial cell supporting coating thereon.

In a particularly preferred embodiment, the invention provides a treated epikeratophakia lens comprising a synthetic lens, a surface modifying composition covalently bound to the lens, the surface modifying composition comprising a lysine polymer modified to contain pendant groups derived from N-hydroxy-succinimidyl-4-azidobenzoate or methyl 1-4-azidobenzoimidate, and an epithelial cell-supporting coating bound to the surface modifying composition and disposed on an exposed surface of the thus-treated lens. The epithelial cell-supporting coating preferably is covalently bound to the surface modifying

composition. The epithelial cell-supporting coating also may be crosslinked in situ.

Detailed Description of the Preferred Embodiments

According to the present invention, a synthetic surface which ordinarily is not well suited to the binding of proteins is rendered more suitable for protein binding by the application of a surface modifier composition. This aspect of the invention is applicable to a wide variety of synthetic surfaces. This specification describes the invention in connection with hydrogels of, e.g., N-vinylpyrrolidone / methyl methacrylate copolymers commonly employed in implantable lenses, but is not so limited. Other hydrogels which may be modified according to the present invention include polymers of 2-hydroxyethylacrylate (e.g. polymacon), various copolymers of 2-hydroxyethylmethacrylate (e.g. hafilcon A and B, vifilcon A, tetrafilcon, dimefilcon, bufilcon, perfilcon, etc.), copolymers of N-vinylpyrrolidone (e.g. lidofilcon A and B, scafilcon A, surfilcon, vifilcon, filcon YA, etc.) and hydrogels containing collagen, for example as described in U.S. patents 4,452,925 and 4,388,428 and in P.N.A.S., USA, 77 (No. 4), 2064-2068 (1980).

The invention is also useful for providing modified surfaces on vascular graft implants. Such implants are fabricated, for example, from Dacron, polyurethanes, polypropylene, silicone, crosslinked collagens, collagen-plastic composites or phospho-lipid polymers.

Hydrogels are preferred constituents of epikeratophakia lenses due to their permeability and, consequently, their ability to transport oxygen, glucose and other nutrients and metabolites. Tissue

culture plates are other synthetic surfaces which are enhanced by the methods of the present invention.

5 The surface modifier composition can be based on virtually any polymer having a plurality of pendant groups. Preferred polymers include a plurality of pendant amino and/or carboxyl groups and are exemplified by poly(amino acid)s such as poly(lysine). Other polyamines can be used, e.g. polyethyleneimine, as can other compounds with high amine content. In the alternative, bio-compatible compounds with high carboxyl content may be used.

10 The molecular weight or chain length of the polymer employed in the surface modifier composition is not critical to the invention. For example, poly-L- and poly-D-lysines of 90,000 to 490,000 daltons have been used successfully in the surface modification method of the invention. Polymers of lower (or higher) molecular weight also are useful.

15 In order to provide a highly stable modified surface, the surface modifier composition is covalently bound to the synthetic surface. Covalent binding is accomplished via the use of appropriate coupling agents. In general, in surface modifier compositions based on polymers having a plurality of pendant groups, the pendant groups first are converted into functional groups capable of forming highly reactive radicals. The polymers then are covalently bound to the synthetic surface by converting the groups to their corresponding highly reactive functional groups, preferably via photolysis. The highly reactive functional groups then covalently couple with the synthetic surface.

20 Advantageously, the synthetic surface does not have to be derivatized or otherwise specially treated prior to the application of the surface modifier

composition. Pre-treatment of a hydrogel surface with a methyl alcohol solution (which causes a swelling of the copolymer) does enhance binding, however, and thus is recommended.

5 One preferred binding method is to covalently couple to the synthetic surface a surface modifier composition based on a poly(lysine) which has been modified so that about 10 mol percent of the pendant amino groups have been modified by a functional group
10 containing a moiety capable of being converted into a nitrene or other highly reactive group. Nitrene groups are highly reactive with the synthetic surface and are formed, for example, by the photolysis of an azido ($-N_3$) group.

15 A portion of the pendant amino groups of a poly(lysine) polymer can be derivatized by reacting the lysine polymer with N-hydroxysuccinimidyl-4-azidobenzoate ("HSAB"), a polyfunctional compound which contains an amine-reactive group as well as an azido
20 group. Upon incubation of the hydrogel lens with the HSAB-derivatized poly(lysine), and photolysis with UV light (typically in the 265-275 nm range), the poly(lysine) chains are covalently bound to the hydrogel. Crosslinking among polymer chains also
25 occurs. Methyl 1-4-azidobenzoimidate (MABI) is another compound useful for modifying the lysine polymer. Those skilled in the art will be able to select other appropriate polyfunctional coupling agents.

30 The present invention also provides for the inclusion of a variety of other materials in the surface modifier compositions. If desired, the compositions can contain medicaments and/or other materials which promote wound healing. For example, an antibiotic material can be dispersed in the surface

modifying composition. Suitable antibiotics include gentamicin, neomycin, bacitracin and the like. In addition, other antimicrobial agents, antiviral agents, anti-inflammatory agents, anti-protease agents, hormones, vitamins, analgesics, chelating agents, mitogenic agents (including growth factors) and the like may be incorporated in the surface modifying composition.

Preferred materials for incorporation into the surface modifier compositions are biological materials which are known to support the attachment, growth and migration of epithelial cells. These materials are referred to as "epithelial cell-supporting" materials herein. Advantageously, materials to be incorporated within the surface modifying compositions do not need to be modified or derivatized. Useful native, underivatized materials include (but are not limited to) collagen types I, III, IV and/or others, fibronectin, laminin, chondroitin sulfate and virtually any other protein or other desired material desired to be covalently attached to the synthetic surface. If desired, these materials may be altered, derivatized or crosslinked prior to being combined with the HSAB-modified poly(lysine) and applied to the hydrogel. Upon photolysis, the included material is crosslinked by some of the nitrene groups attached to the poly(lysine), whereas other nitrene groups attached to the poly(lysine) covalently bind to the lens surface. Thus the lens (or other synthetic surface) is now coated with a covalently-attached layer of a surface modifier composition.

A derivatized poly(lysine) molecule is prepared by incubation of the native poly(lysine) with the bifunctional crosslinker HSAB under appropriate

conditions. Any unreacted crosslinker is removed by ultrafiltration or other non-destructive methods such as dialysis. In addition to poly(lysine), other polymers capable of binding to a bifunctional crosslinker containing a secondary group capable of forming a highly-reactive radical upon exposure to light may be used in this process.

Example I

An HSAB-derivatized poly(lysine) is prepared according to the procedure described in detail in Example V. HSAB is available from Pierce Chemical Company, Rockford, IL, USA. A hydrogel lens prepared from an N-vinylpyrrolidone, methyl methacrylate copolymer is placed in a chamber anterior side up and incubated with the HSAB-derivatized poly(lysine) solution (2.0 to 10.0 mg/ml, preferably 5.0 mg/ml) (which is hereinafter referred to as "HSAB-plys"), with or without 10-20% MeOH added to swell the hydrogel during coating. The lens is then irradiated with UV light for 4 to 10 minutes per coat for 5 to 10 coats. The lens is then extracted in aqueous solutions of plain water, saline or 0.05 M glacial acetic acid to remove unbound HSAB-plys.

The coating is visualized on a test lens from the lot by a novel Coomassie™ staining/destaining process that visualizes only covalently bound HSAB-plys on the hydrogel lens. The coated lens and a control (uncoated) lens are submerged in a stain composed of 0.1 to 0.25 % (w/v) Coomassie Brilliant Blue R (Sigma B-0630), 7 to 10 % glacial acetic acid and 25 % methanol in water (see Laemmli, U.K., Nature 227, 680 (1970)). Alternately, a stain composed of 0.1 to 0.25 % (w/v) Coomassie Brilliant Blue R, 0 to 10 % glacial

acetic acid, 45 % methanol and 45 % acetone (balance water, methanol and/or acetone) may be used. While the Laemmli process employs acetic acid to fix the protein(s) of interest to an acrylamide gel, the use of acetic acid is not required in this process as the poly(lysine) is covalently bound to the synthetic surface.

The lenses are incubated in the stain for 20 to 30 minutes. The lenses are extracted with three 20-minute extractions (or until the control lens is completely clear) of destaining solution composed of 0 to 10 % (w/v) glacial acetic acid, 45 % methanol and 45 % acetone (balance water, methanol and/or acetic acid) to remove the unbound Coomassie stain. The acetone advantageously swells the hydrogel to aid the release of unbound stain. Under these staining/destaining conditions unbound HSAB-plys (or plys alone) is removed from the lens and only lenses to which the poly(lysine) is covalently bound retain the stain.

These lenses, having surfaces modified with HSAB-plys alone, are capable of binding epithelial cells, but the cells do not seem to spread well. Thus it is desirable to bind collagen or other epithelial cell-supporting materials to this poly(lysine) in order to support epithelial growth. This may be done in one step, by incorporating an epithelial cell-supporting material within the surface modifier composition, or in several steps, by providing an epithelial cell-supporting coating over the surface modifier composition.

Variations in the destaining solution mentioned above are possible. In general, destaining solutions containing 10-45 % acetone, 25-45 % methanol, 10-25 % glyme (dimethoxyethane), balance water and/or glacial

acetic acid (HOAc) are useful for removing unbound Coomassie-type stain while swelling the hydrogel (or other polymer). Specific examples are set forth below wherein all amounts are percent (w/v):

5		<u>Acetone</u>	<u>MeOH</u>	<u>H₂O</u>	<u>HOAc</u>	<u>Glyme</u>
	1)	45	45	0-10	0-10	
	2)	10	45	35	-	10
	3)	25	-	50	-	25
	4)	10	25	55	-	10

10 The acetone component of the destaining solution appears to function as a solvent which softens the poly(methyl methacrylate) component of the hydrogel to aid in the release of unbound stain. Other solvents which function in a similar manner may be employed in
15 lieu of or in combination with acetone. Of course, the choice of particular solvents will be based on the composition of the synthetic surface to be treated in accordance with the invention.

Example II

20 In a one step method, HSAB-plys and unmodified collagen may be simultaneously covalently bound to the hydrogel surface in the following manner. A hydrogel lens is incubated with a solution containing both HSAB-plys and combinations of collagen I, III and IV
25 (optionally along with fibronectin, laminin, chondroitin sulfate or any other desired material) in a range from 100:1 to 1:100 ratio by weight HSAB-plys:collagen (or other ratios allowing some of the HSAB moieties on the poly(lysine) to be used for
30 coupling to the hydrogel lens, and some to be used for coupling to the collagen). Multiple coats (5-10) are coupled via irradiation onto the lens. The protein coating may be visualized by staining as described above. Alternate specific stains may be used to

distinguish collagen or other materials from the poly(lysine) staining; however, Coomassie stain can also distinguish the collagen/poly(lysine) coating from a poly(lysine) coating using the procedure described in
5 Example I. As further evidence of the covalent binding of collagen and poly(lysine) to the hydrogel surfaces, autoclaving these coated lenses results in retention of the collagen/poly(lysine) coating as visualized by the staining procedure. However, cell culture results on
10 such autoclaved lenses are negative, i.e. cells do not adhere or spread on these lenses. Thus, even when the collagen is denatured by autoclaving, it is still covalently bound to the hydrogel surface.

Example III

15 In a two step method, HSAB-plys and collagen (or other molecules) may be bound to the surface of the hydrogel. First, HSAB-plys is covalently bound to the surface by incubation with the hydrogel in the presence of UV light, as discussed above. Secondly, collagen,
20 and/or other molecules containing carboxyl groups are incubated with the poly(lysine) coated lens in the presence of a crosslinker such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide ("EDC", available from Pierce Chemical Company, Rockford, IL, USA), or other
25 carbodiimides, which crosslinks the collagen to the bound poly(lysine), and thus to the hydrogel lens. If other derivatized polymers are used, instead of poly(lysine), and covalently bound to the hydrogel surface, then other crosslinkers are chosen which can
30 crosslink functional groups on the polymer to materials which will support epithelial growth, or other molecules as desired. Thus both homobifunctional and heterobifunctional crosslinkers may be used where

appropriate. Multiple coats (4-5) are covalently bound to the surface in this fashion. Extensive extraction with saline or a solution of 100 to 500 µg/ml gentamicin sulfate in saline is performed to remove any non-covalently bound materials and reagents.

The EDC crosslinking may be done at a low pH, as is standard, or at physiological pH using N-hydroxysulfosuccinimide ("Sulfo-NHS" also available from Pierce Chemical Company) as a co-reactant in order to gently couple sensitive molecules or materials, such as laminin or basement membrane extract, which may be desired in the coating. Laminin may be added during the neutral pH EDC crosslinking. After an incubation of the lens with the EDC/collagen/low pH mixture, the pH may be raised before the addition of laminin or other sensitive molecules to be bound.

The above lenses, covalently coated with poly(lysine) and collagen (and/or other epithelial cell-supporting materials) may be further crosslinked with glutaraldehyde alone, or glutaraldehyde followed by sodium cyanoborohydride, to stabilize the lenses to collagenase activity and to provide a more desirable coating for epithelial migration. The coated lenses may be crosslinked with a low concentration glutaraldehyde solution (0.2%), and/or with a high concentration solution (up to 2.0%), or other concentrations, in a sodium phosphate/sodium chloride buffer. The lenses are extensively extracted and then treated with a borate/glycine buffer to neutralize any unreacted glutaraldehyde. The unbound materials are removed by extensive extraction in aqueous solutions of saline or gentamicin sulfate in saline as described above. The stability of the coating to collagenase digestion on such lenses is greater than that of

control lenses without glutaraldehyde crosslinking, as visualized by the stain/destaining method. In cell culture and in animal studies (rabbits and cats) these lenses perform well, indicating that post or
5 intermediate crosslinking with concentrations ranging from 0.2% to 2.0% glutaraldehyde does not deter epithelial cell growth, and may in fact enhance the growth of epithelial cells. The further treatment of these lenses with sodium cyanoborohydride to further
10 stabilize the crosslinks formed by the glutaraldehyde (to prevent possible reversal with time) also does not interfere with epithelial cell growth.

Additionally, the above lenses which have poly(lysine) surface modifier and collagen layers (and
15 optionally also include fibronectin, laminin, or other desired materials), followed by glutaraldehyde treatment, may now have additional coats of collagen I, III and/or IV, laminin, fibronectin, or any combination of these or other appropriate molecules to support
20 epithelial growth, bound to the lens by the methods described above. The additional coats will present a more native surface to the spreading epithelial cells. If desired, these extra coats may also be followed by a crosslinking step (with glutaraldehyde for example)
25 which further crosslinks all coats. Hydrogel lenses treated as above have given 100% cell confluence in 1-2 days in cell culture. When implanted in rabbits, the lenses are essentially completely re-epithelialized in 4-7 days.

30 The following examples are intended to illustrate further the practice of the invention and are not intended to limit its scope in any way.

Example IVCoupling collagen directly to a hydrogel surface
which contains carboxyl groups

The hydrogel in this Example is a polymer
5 consisting of vinyl pyrrolidone and methyl
methacrylate, containing methacrylic acid as a source
of carboxyl functional groups. Collagen is type I,
calf skin, 2.5 mg/ml as supplied in acidic solutions.
The hydrogel was incubated with collagen and EDC for 1
10 hr. at room temperature in a pH 4 sodium phosphate
buffer, and subsequently rinsed. As visualized by
protein staining, the hydrogel acquired a thin protein
coating.

Example V

15 Preparation of poly-L-lysine derivatized with a
heterobifunctional crosslinking reagent, HSAB

Poly-L-lysine (490,000 daltons), 500 mg, is
dissolved into 95 ml of 0.5 M triethanolamine, 0.2 M
NaCl buffer, pH 8.3-8.4. A 10% molar ratio of HSAB to
20 total available amino groups is dissolved in a small
volume of DMF (3 ml) in the dark. The HSAB in DMF is
then added, while stirring, to the poly-L-lysine and
incubated at 4°C in the dark for 2 hours, or until the
process of binding is complete as determined by HPLC
25 using a size exclusion column. The HSAB-derivatized
poly-L-lysine (HSAB-plys) is exchanged into water via
ultrafiltration for several changes, is sterile
filtered and stored in the dark at 4° C until use.

Example VICoupling HSAB-poly-L-lysine to a non-functionalized hydrogel surface by exposure to UV light

5 The hydrogel (vinyl pyrrolidone, methacrylate copolymer with no carboxyl or amine functional groups) lenses are incubated with a 5 mg/ml solution of HSAB-plys (from example V) and photolyzed with UV light for 10 minutes. The solution is exchanged, and the process repeated for a total of 10
10 times to obtain 10 coats of poly-L-lysine covalently bound to the lens surface and to itself.

The lenses are rinsed extensively and put into cell culture, or implanted into rabbits. Cell culture results show isolated patches of cells which show up to
15 40% attachment to the surface by day 2-5. These results imply that although cell attachment may be achieved, cell spreading is not achieved on this surface. Rabbit implants were stable, but epithelialization of the lens surface did not occur.

20

Example VIICoupling HSAB-poly-L-lysine and collagen simultaneously to a non-functionalized hydrogel surface by exposure to UV light

Hydrogel lenses were incubated with solutions
25 containing molar ratios of 10:1, 30:1, and 100:1 collagen IV : HSAB-plys, with collagen concentration of 2 mg/ml. Ten coats were applied using 10 minute exposures to UV light. Lenses with such coatings support epithelial growth in cell culture, with 85-90%
30 coverage by day 1, and 100% by day 4. Rabbit implants show epithelial growth up to the trephine cut by day 2, and at best, epithelial coverage up to 35% by day 6, followed by complete retreat of the epithelium from the lens by day 8.

Example VIIICrosslinking of coated hydrogel lenses
with glutaraldehyde

Lenses were coated with UV light as in example VII
5 with 15:1 collagen IV to HSAB-plys. The coated lenses
were then incubated for two 45 minute treatments with
solutions of 0.2% glutaraldehyde in a 0.5 M sodium
phosphate, 0.15 M sodium chloride, pH 7.4 buffer.
Lenses were rinsed with water for injection and
10 incubated with a 0.05 M sodium borate, 0.025 M glycine
solution for three incubations of 20 minutes each,
followed by extensive rinsing in aqueous solutions.
These lenses support epithelial growth in cell culture,
with 90% coverage by day 1, and 100% by day 2. Rabbit
15 implants show a maximum coverage of the lenses of 40%
by day 3 to day 8, followed by regression to 0% by day
14. A cat implant showed a stable maximum coverage of
70% after 5 weeks, followed by a 3 day regression to
50% and extrusion.

20

Example IXAddition of 1% Chondroitin Sulfate
to the coating of hydrogel lenses

Lenses were coated using UV light, similarly to
example VII, with 10 coats for 5 minutes UV each and a
25 15:1 cell-supporting material : HSAB-plys solution,
with the cell-supporting material consisting of a
solution of 2.0 mg/ml collagen and a 0.02 mg/ml
chondroitin sulfate. Lenses were treated with
glutaraldehyde as in Example VIII. Rabbit implant
30 results are similar to those of Example VIII with a
maximum of 40% coverage by day 4, and regression to 20%
by day 9.

Example XAddition of collagen coats via carbodiimide coupling to the collagen:poly-lysine coated lenses

Lenses were prepared similarly to those in example VII using collagen IV:HSAB-PLYS in a 15:1 molar ratio, for 9-10 coats. These lenses were then incubated with 2.0 mg/ml collagen IV and 19.2 mg/ml EDC under acidic conditions for 4 coats of 20 minutes each. Lenses had either no further additions, or had additions of 1% by weight of chondroitin sulfate (CS), fibronectin (Fn), or chondroitin sulfate and fibronectin. The lenses were treated with glutaraldehyde as in example VIII. Results for lenses with the following EDC coats are seen in Table I. The expressed percentages refer to re-epithelialization.

TABLE I

20	Col IV:	- Cell culture, 80% by day 2, 90% by day 6, healthy cells. - Rabbit implant, 85% by day 7, 100% by day 8 through 9, with regression to 10% by day 14.
	Col IV + 1% CS:	- Cell culture, 80% by day 2, healthy cells.
25	Col IV + 1% Fn:	- Rabbit implant, 100% by day 4, 90% by day 8, with regression to 10% by day 14.
30	Col IV + 1% Fn	
	+ 1% Cs:	- Cell culture, 80% by day 2, 95-98% by day 6 with some rounded cells. - Cat implant, 100% epithelial coverage, stable out to 30 weeks at last observation.

Example XI

5 Addition of HSAB-plys with UV, neutral pH
 EDC coating, laminin, 2.0% glutaraldehyde
 crosslinking, and extra EDC overcoats of
 collagen IV, chondroitin sulfate and laminin
 to lenses coated as in example VIII, with
 various other treatments as indicated
 below (Types 1-7)

10 All lenses were coated in the following manner
 (steps 1-7):

1. 5 HSAB-poly-L-lysine UV coats with 10% MeOH,
 irradiated for 4 minutes each.
2. 10 coats Col I:HSAB-poly-L-lysine, 12:1 ratio by
 weight, at 1 mg/ml collagen and irradiated as in
15 step 1.
3. 4 coats EDC/NHS-sulfo* pH 7.4 with collagen IV at
 2 mg/ml and laminin**.
4. 0.2% glutaraldehyde overnight under the conditions
 in example VIII.
- 20 5. 2.0% glutaraldehyde for 45 minutes under the same
 conditions.
6. 2 coats EDC/NHS-sulfo pH 7.4 with collagen IV,
 laminin, and 0.2% chondroitin sulfate.
- 25 7. One of the following differences or additions to
 the treatment:

 Type 1: No further treatment.

 Type 2: Poly-D-lysine was used in steps 1 and 2.

 Type 3: EDC/NHS-sulfo coats of underivatized
 poly-lysine were added in between the
30 first three coats of step 3.

 Type 4: A 2.0% glutaraldehyde crosslinking step
 after all coats (after step 6 above)
 under the same conditions as in Example
 VIII.

Type 5: A 2.0% glutaraldehyde step as in Type 4 followed by sodium cyanoborohydride treatment.***

5 Type 6: Sodium cyanoborohydride treatment alone after all coats (after step 6 above).

Type 7: Lenses were etched before coating to give a rough coating surface.

* EDC/NHS-sulfo was 19.2 mg/ml EDC, 9.6 mg/ml NHS-sulfo at neutral pH in sodium phosphate buffer.

10 ** Laminin was provided by adding 13 µg/ml laminin to the collagen mixture.

*** Sodium cyanoborohydride was provided by adding 50 mM sodium cyanoborohydride in 0.5 M sodium acetate, pH 4.4.

15 The results obtained are as follows:

Types 1 through 6 lenses were implanted in rabbits. The best lens from Type 5 achieved 98 % coverage by day 8 and maintained 75 % coverage as of day 62. The best lens from Type 4 achieved 80 to 85 % coverage by day 7 and maintained 70 % coverage as of day 29. The best lens from Type 3 achieved 70 to 75 % coverage by day 6 and maintained 60 % coverage as of day 22. Lenses from Types 1, 2 and 6 achieved maximum epithelial cell coverage of around 70 % and regressed to 15 % or less by day 40.

25 Although the present invention has been described in connection with certain preferred embodiments and specific Examples, it is not so limited. Variations within the scope of the appended claims will be readily apparent to those skilled in the art.

30

We Claim:

1. A method for modifying a synthetic surface on an implantable prosthetic device, comprising:

5 a) applying to the synthetic surface a surface modifying composition comprising a polymer having pendant groups capable of being converted to reactive functional groups capable of covalently coupling to the synthetic surface; and

10 b) converting the pendant groups to reactive functional groups and thereby covalently binding the surface modifying composition to the synthetic surface.

2. A method according to claim 1 wherein the prosthetic device is a lens.

3. A method according to claim 1 wherein the surface modifying composition comprises a polymer having pendant azido groups.

4. A method according to claim 1 wherein the surface modifying composition comprises a poly(amino acid).

5. A method according to claim 4 wherein the amino acid is lysine.

6. A method according to claim 1 wherein the surface modifying composition comprises a modified poly(lysine) which contains about 10 mol percent of pendant groups capable of being converted to nitrene functional groups.

7. A method according to claim 6 wherein said pendant groups comprise azido groups.

8. A method according to claim 7 wherein said pendant groups are derived from N-hydroxy-succinimidyl-4-azidobenzoate or methyl 1-4-azidobenzoimide.

9. A method according to claim 1, 6 or 8 wherein said converting step comprises exposing said surface modifying composition to light.

10. A method according to claim 1 wherein said surface modifying composition further comprises an epithelial cell-supporting material.

11. A method according to claim 10 wherein said epithelial cell-supporting material comprises one or more of collagen I, collagen III, collagen IV, fibronectin, chondroitin sulfate and laminin.

12. A method for coating a synthetic surface with an epithelial cell-supporting coating, comprising:

5 a) applying to a synthetic surface a surface modifying composition comprising a polymer having pendant groups capable of being converted to reactive functional groups capable of covalently coupling to the synthetic surface;

10 b) converting the pendant groups to reactive functional groups and thereby covalently binding the surface modifying composition to the polymeric surface to thereby modify the synthetic surface; and

c) subsequently applying an epithelial cell-supporting coating onto the modified synthetic surface.

13. A method according to claim 12 wherein step (c) comprises covalently binding the epithelial cell-supporting coating to the surface modifying composition.

14. A method according to claim 13 wherein said covalent binding is carried out by a covalent coupling agent.

15. A method according to claim 14 wherein said covalent crosslinking agent comprises (1-ethyl-3-(3-dimethyl)-aminopropyl)carbodiimide.

16. A modified synthetic surface for supporting the attachment, growth and migration of epithelial cells, comprising:

a) a synthetic surface;

- 5 b) a surface modifying composition covalently bound to the synthetic surface and thereby modifying the synthetic surface; and
- c) an epithelial cell-supporting coating disposed on the modified surface.

17. A modified synthetic surface according to claim 16 wherein the epithelial cell-supporting coating is covalently bound to the surface modifying composition.

18. A modified synthetic surface according to claim 17 wherein the epithelial cell-supporting coating is covalently bound to the surface modifying composition via functional groups derived from (1-ethyl-3-(3-dimethyl-aminopropyl) carbodiimide.
- 5 19. A modified synthetic surface according to claim 18 wherein the surface modifying agent is based on a polymer having a plurality of pendant amino or carboxyl groups.

20. A modified synthetic surface according to claim 19 wherein the polymer comprises a poly(amino acid).

21. A modified synthetic surface according to claim 16 wherein the epithelial cell-supporting coating is crosslinked.

22. A treated epikeratophakia lens comprising:

- a) a lens comprised of a synthetic material;
- b) a surface modifying composition covalently bound to the lens, the surface modifying composition comprising a lysine polymer modified to contain pendant groups derived from N-hydroxy-succinimidyl-4-azidobenzoate or methyl 1-4-azidobenzoimidate; and
- 5 c) an epithelial cell-supporting coating bound to the surface modifying composition.

23. A lens according to claim 22 wherein the epithelial cell-supporting coating is covalently bound to the surface modifying composition.

24. A lens according to claim 23 wherein the epithelial cell-supporting coating is crosslinked.

25. A lens according to claim 24 wherein the epithelial cell-supporting coating comprises one or more of collagen I, collagen III, collagen IV, laminin, fibronectin and chondroitin sulfate.

26. A staining/destaining process for visualizing proteins and poly(amino acids) which are covalently bound to a methyl methacrylate-containing hydrogel surface, comprising:


a) staining a hydrogel with a stain solution comprising Coomassie Blue and

b) destaining with a destaining solution comprising a solvent for methyl methacrylate

27. A process according to claim 26 wherein the destaining solution comprises acetone.

INTERNATIONAL SEARCH REPORT

International Application No. **PCT/US90/05028**

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ¹		
According to International Patent Classification (IPC) or to both National Classification and IPC IPC(5): A61F 2/02 US CL.: 623/11		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁴		
Classification System	Classification Symbols	
US	623/4-6,11 351/160R 427/2	436/86,89
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁵		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ¹¹		
Category ¹²	Citation of Document, ¹³ with indication, where appropriate, of the relevant passages ¹⁴	Relevant to Claim No. ¹⁵
X	US, A, 4,676,790 (KERN) 30 June 1987 See figures 3 and 4.	16-17,19,21
X Y	WO, A, 8,904,153 (GIBSON et al.) 18 May 1989 See the entire document.	1-14,16-17,19-25 15,18
X Y	WO, A, 8,906,945 (BIRARDOT) 10 August 1989 See pages 13 and 30.	1,3-5,9 6-8
Y	US, A, 3,826,678 (HOFFMAN et al.) 30 July 1974 Note the discussion in column 6.	15
X	US, A, 4,656,083 (HOFFMAN et al.) 07 April 1987 Note the discussion in columns 4 and 5.	1,9-10,16-17,21
X	US, A, 4,704,131 (NOISHIKI et al.) 03 November 1987 Note the abstract.	1
X Y	US, A, 4,828,563 (MULLER-LIERHEIM) 09 May 1989 See column 1, lines 50-63; column 2, lines 59-61.	1-2,10-14,16-17 6
X,P	US, A, 4,919,659 (HORBETT et al.) 24 April 1990 See column 2, lines 52-69; column 3, lines 58-69; column 7, lines 25-35.	1,4-6,9-14,16- 17,21
Y,P	WO, A, 9,000,887 (GUIRE et al.) 08 February 1990 See the entire document.	1-25
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁶ Special categories of cited documents: ¹⁷</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search ¹⁸		Date of Mailing of the International Search Report ¹⁹
11 FEBRUARY 1991		27 FEB 1991
International Searching Authority ¹		Signature of Authorized Officer ²⁰
ISA/US		 DAVID H. WILLSE

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers _____ because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claim numbers _____ because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out², specifically:

3. ☐ Claim numbers _____ because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☒ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING³

This International Searching Authority found multiple inventions in this international application:

Group 1: claims 1-25, which are drawn to a modified synthetic surface.

Group 2: claims 26-27, which are drawn to a staining/destaining process.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all of the claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers those claims of the international application for which fees were paid, specifically claims:

3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report covers the invention first mentioned in the claims; it is covered by claim numbers:

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority does not invite payment of any additional fee.

Remark on Protest

- ☒ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No ¹⁸
T	US, A, 4,979,959 (GUIRE et al.) 25 December 1990 See the entire document.	1-25
T	US, A, 4,983,181 (CIVERCHIA) 08 January 1991 See the abstract and the figures.	16
T	US, A, 4,976,733 (GIRARDOT) 11 December 1990 See the entire document.	1,3-9
T	US, A, 4,955,901 (NISHIGUCHI et al.) 11 September 1990, See the entire document.	1-25
A	US, A, 4,715,858 (LINDSTROM) 29 December 1987 See the figures.	1-25
A	US, A, 4,836,884 (MCAUSLAN) 06 June 1989 See column 3, lines 10-18.	1-25
T	US, A, 4,959,074 (HALPERN et al.) 25 September 1990 See column 5, lines 30-59.	26-27
Y	US, A, 4,782,027 (LEE et al.) 01 November 1988 See the entire document.	26-27